AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 272 min read$CYTK

Blum Robert I sold $607K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $80.87 ($0.61M total) on 2026-07-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published Jul 27, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 27, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CYTK
Neutral
medium confidence
Mentioned
$CYTK
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKNeutralLow
01

Why it matters

The disclosure provides a concrete, same-day datapoint on insider selling activity, but it does not introduce new company fundamentals.

02

Market read

Traders may briefly reassess sentiment around insider behavior, but the planned nature of the sale limits fundamental implications.

03

What to watch

The article does not state whether other insiders sold/bought around the same time, nor does it provide context on total CEO holdings or prior sale cadence.

Relevance 4/10Novelty 5/10Timing: filed 2026-07-27, after-hours SEC Form 4 disclosure

Background

This is an SEC Form 4 insider transaction for Cytokinetics, reported by the company’s President and CEO.

Company-level read

Ticker impact

$CYTKNeutralMedium confidence
Context

CYTOKINETICS CEO Robert Blum filed a Form 4 selling 7,500 shares at $80.87 on 2026-07-27 under a 10b5-1 plan.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional catalyst beyond typical insider-sale interpretation.

Evidence & confidence

The filing is primary-source and time-stamped, but it is a planned 10b5-1 sale and the article provides no new operational, financial, or regulatory developments.

Market effects

Sector

No direct sector read-across; this is a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.

Key entities

  • issuer
    CYTOKINETICS INC

    US-listed company whose CEO insider sale is disclosed on Form 4.

  • insider
    Blum Robert I

    President and CEO reporting an open-market sale of 7,500 shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

OCT 13
$CYTKHigh

Cytokinetics Highlights Exercise Capacity, Responder Data For Aficamten In NHCM At HFSA 2026

Cytokinetics (CYTK) presented data from the ACACIA-HCM trial at the HFSA 2026 meeting, showing aficamten improved exercise performance and clinical outcomes in non-obstructive HCM patients. The drug demonstrated significant benefits in exercise capacity, symptom relief, and safety, with 53% of patients showing improvements across multiple domains. CYTK reported a Q2 2026 net loss of $198.8M and $25.3M in aficamten revenue, with cash reserves of $1.7B.

rttnews.com2 min
OCT 12
$CYTKMed

Cytokinetics presents additional aficamten data from trial

Cytokinetics (CYTK) presented additional data from its ACACIA-HCM trial at the Heart Failure Society of America Annual Scientific Meeting. Aficamten showed statistically significant improvements in exercise performance and clinical response in patients with non-obstructive hypertrophic cardiomyopathy. The company plans to submit a supplemental New Drug Application to the FDA this quarter for this indication.

uk.investing.com1 min
OCT 12
$CYTKMed

Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo.

Cytokinetics (CYTK) presented additional data from the ACACIA-HCM trial at the HFSA Annual Scientific Meeting. The study showed aficamten improved exercise performance and safety in non-obstructive HCM patients. Serious heart failure events occurred in 4.7% of aficamten patients vs. 1.2% on placebo. The company plans to submit a supplemental New Drug Application to the FDA this quarter.

stocktitan.net4 min